Germany CAR T-Cell Therapy Market (2026-2031)
The Germany CAR T-Cell Therapy Market was valued at $601.1 Million in 2026 and projected to reach to $1089.3 Million by 2031, representing a compound annual growth rate of 12.6%. Germany's CAR T-Cell Therapy market is poised for significant expansion through 2031, driven by increasing prevalence of hematologic malignancies, growing healthcare expenditure, and strong government support for biotechnology innovation.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Germany CAR T-Cell Therapy Market Trends and Insights
- Germany's advanced healthcare infrastructure, strong pharmaceutical R&D capabilities, and robust regulatory framework position the country as a key hub for CAR T-cell innovation in Europe.
- The market growth in Germany is driven by increasing adoption of personalized cancer therapies, rising prevalence of hematologic malignancies, and expanding reimbursement policies that support patient access to these cutting-edge treatments. Germany's commitment to precision medicine and its established clinical trial networks accelerate the commercialization of CAR T-cell therapies across the forecast period.
- The country's healthcare system emphasizes evidence-based treatment protocols, which supports the integration of CAR T-cell therapies into standard oncology practice.
- By 2031, Germany is expected to maintain its position as a leading market for CAR T-cell therapeutics in Europe, driven by continued investment in immunotherapy research and growing patient demand for innovative cancer solutions..
Key Market Statistics
- CAGR (2026-2031) 12.6% CAGR
- Market Size, 2026 ~USD 601.1 Million
- Forecast, 2031 ~USD 1089.3 Million
- Country Germany
Germany CAR T-Cell Therapy Market Overview
Market Valuation Growth :
Germany's CAR T-Cell Therapy market is valued at USD 601.1 million in 2026 and is projected to reach USD 1,089.3 million by 2031, demonstrating robust expansion driven by increasing adoption of advanced immunotherapies.
Strong CAGR Performance :
The German market is growing at a CAGR of 12.6% from 2026 to 2031, slightly below the global average of 13.7%, reflecting steady market maturation and consistent demand for CAR T-cell treatments.
Healthcare Infrastructure Excellence :
Germany's advanced healthcare system, world-class research institutions, and established pharmaceutical manufacturing capabilities position it as a leading European hub for CAR T-cell therapy development and commercialization.
Regulatory Framework Advantage :
Germany benefits from a robust regulatory environment under the European Medicines Agency (EMA), facilitating faster approval pathways and enabling German biotech companies to lead CAR T-cell innovation across Europe.
Germany CAR T-Cell Therapy Market Dynamics
- The country's established pharmaceutical ecosystem and academic research centers are accelerating clinical trial activities and treatment accessibility. Key growth catalysts include rising patient awareness, expanding reimbursement coverage by German health insurers, and strategic partnerships between domestic biotech firms and international pharmaceutical companies.
- Germany's commitment to precision medicine and cellular immunotherapy positions it as a critical market for CAR T-cell therapy adoption in Europe, with sustained investment in manufacturing infrastructure and clinical capabilities expected through the forecast period..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Merck KGaA
- Thermo Fisher Scientific Inc.
- SANOFI
- NOVARTIS
- Pfizer Inc.
Key Takeaways
- Germany's CAR T-Cell Therapy market is valued at USD 601.1 million in 2026 and will reach USD 1,089.3 million by 2031, growing at 12.6% CAGR.
- Germany's advanced healthcare infrastructure and strong R&D ecosystem position it as a leading European hub for CAR T-cell innovation and commercialization.
- Expanding reimbursement policies and increasing adoption of personalized cancer therapies are key drivers of market growth in Germany through 2031.
- Germany's emphasis on precision medicine and established clinical trial networks support rapid integration of CAR T-cell therapies into standard oncology practice.
CAR T-Cell Therapy Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | CD19/20 (Target) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 13.7% from 2026 to 2031 |
| Largest Segment | CD19 (Target) |
| Market Size Base Year (Billions) | ~USD 7.25 (2026) |
| Revenue Forecast (Billions) | ~USD 13.78 (2031) |
| Segments Covered | Product, Target, Indication |
Germany CAR T-Cell Therapy Market Report Segmentation
3 segment dimensions are covered across the global market.
By Product
- Abecma
- Breyanzi
- Carvykti
- Kymriah
- Other Products
- Tecartus
- Yescarta
By Target
- Bcma
- Cd19
- Cd19/20
- Cd7
- Other Targets
By Indication
- Acute Lymphoblastic Leukemia (All)
- B-Cell Lymphoma (Bcl)
- Multiple Myeloma
- Other Indications
GERMANY: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| HOSPITALS | 257.1 | 339.6 | 383.7 | 431.1 | 485.3 | 548.5 | 621.6 | 706.8 | 13 |
| LONG-TERM CARE FACILITIES | 17.4 | 22.6 | 24.3 | 26 | 27.7 | 29.6 | 31.6 | 33.8 | 6.8 |
| SPECIALTY CENTERS | 130.4 | 171.6 | 193.1 | 216.1 | 242.3 | 272.8 | 308 | 348.8 | 12.6 |
| TOTAL | 404.9 | 533.8 | 601.1 | 673.2 | 755.4 | 850.9 | 961.2 | 1089.3 | 12.6 |
Target Audience
- Pharmaceutical & Biotech Companies : Manufacturers and developers of CAR T-cell therapies need Germany-specific market data to assess commercial potential, identify partnership opportunities, and optimize product launch strategies in this key European market.
- Healthcare Investment Firms : Private equity and venture capital investors require detailed German market analysis to evaluate investment opportunities in CAR T-cell therapy companies, manufacturing facilities, and healthcare infrastructure projects.
- Hospital & Clinical Networks : German healthcare providers and hospital systems need market intelligence to plan CAR T-cell therapy service expansion, budget allocation, and clinical program development based on market growth projections.
- Medical Device & Diagnostics Companies : Suppliers of supporting technologies and diagnostic tools require Germany-specific market data to identify complementary product opportunities and develop partnerships with CAR T-cell therapy providers.
- Government & Policy Organizations : German health authorities and policy makers need comprehensive market analysis to inform healthcare policy decisions, reimbursement frameworks, and strategic initiatives supporting CAR T-cell therapy accessibility.
Key Companies in the Germany CAR T-Cell Therapy Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| JOHNSON & JOHNSON | United States | Public Company | Oncology and Immunology (Innovative Medicine),Neuroscience, Cardiovascular & Metabolism, Pulmonary Hypertension, Infectious Diseases,Surgery and Interventional (instrumentation, energy, stapling, wound closure, biosurgery, robotic and digital), |
| GILEAD SCIENCES, INC. | United States | Public Company | HIV portfolio (Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, Yeztugo),Liver disease and other antivirals (Epclusa, Livdelzi, Vemlidy, AmBisome),COVID-19 (Veklury), |
| BRISTOL-MYERS SQUIBB COMPANY | United States | Public Company | Eliquis (anticoagulation),Immuno-oncology (Opdivo, Yervoy, Opdualag, Opdivo Qvantig),Hematology (Revlimid, Pomalyst/Imnovid, Reblozyl, Abecma, Breyanzi), |
| NOVARTIS AG | Switzerland | Public Company | Oncology & Hematology (Kisqali, Tafinlar+Mekinist, Jakavi, Pluvicto, Lutathera, Scemblix, Fabhalta),Immunology & Neuroscience (Cosentyx, Xolair, Ilaris, neurology assets),Cardiovascular, Renal & Metabolic (Entresto, Leqvio, other CVRM), |
| AUTOLUS THERAPEUTICS | United Kingdom | Public Company | CD19 CAR-T franchise (AUCATZYL / obe-cel – oncology),Autoimmune CD19 programs (obe-cel in SLE, MS, lupus nephritis),Next-generation oncology pipeline (AUTO1/22, AUTO8, AUTO6NG), |
| JW (CAYMAN) THERAPEUTICS CO., LTD. | China | Public Company | Commercial and late-stage CAR-T for hematologic malignancies (Carteyva, JWCAR201, JWCAR239),Autoimmune indications (relma-cel for SLE and related programs),Solid tumor pipeline (JWATM204/214/203/213, JWTCR001, JWCAR031), |
| CARSGEN THERAPEUTICS HOLDINGS LIMITED | China | Public Company | Zevor-cel (CT053) – BCMA CAR-T for R/R multiple myeloma,Autologous solid-tumor CAR-T (CT041, CT011, CT071, CT0590/CT0596),Autoimmune and B-cell malignancy pipeline (KJ-C2219, KJ-C2320, KJ-C2529), |
| CARTESIAN THERAPEUTICS, INC. | United States | Public Company | Descartes-08 (autoimmune and rare pediatric indications),Descartes-15 (multiple myeloma),Platform and other mRNA cell therapy programs/services, |
| LYELL IMMUNOPHARMA, INC. | United States | Public Company | Hematologic CAR T programs (ronde-cel and platform),Solid tumor CAR T programs (LYL273 and related),Platform technologies and enabling IP (c-Jun, NR4A3 KO, Epi-R, CD62L enrichment), |
JOHNSON & JOHNSON
Johnson & Johnson is a diversified healthcare company founded in 1886 and headquartered in the United States. With 138,200 employees, it operates as a public company serving global markets.
GILEAD SCIENCES, INC.
Gilead Sciences, Inc. is a United States-based biopharmaceutical company founded in 1987. The public company employs 17,000 people and focuses on developing innovative therapeutics.
BRISTOL-MYERS SQUIBB COMPANY
Bristol-Myers Squibb Company is a pharmaceutical company established in 1887 in the United States. As a public company with 32,500 employees, it develops and manufactures pharmaceutical products.
NOVARTIS AG
Novartis AG is a Swiss multinational pharmaceutical company founded in 1996. The public company employs 75,267 people and operates globally in the healthcare sector.
AUTOLUS THERAPEUTICS
Autolus Therapeutics is a United Kingdom-based biopharmaceutical company founded in 2014. The public company has 753 employees and focuses on cell therapy development.
JW (CAYMAN) THERAPEUTICS CO., LTD.
JW (Cayman) Therapeutics Co., Ltd. is a China-based pharmaceutical company founded in 2016. The public company employs 314 people and operates in the therapeutic development sector.
CARSGEN THERAPEUTICS HOLDINGS LIMITED
Carsgen Therapeutics Holdings Limited is a China-based biopharmaceutical company founded in 2014. The public company has 355 employees and specializes in cell therapy development.
CARTESIAN THERAPEUTICS, INC.
Cartesian Therapeutics, Inc. is a United States-based public biopharmaceutical company with 75 employees. The company specializes in cell therapy and therapeutic development.
LYELL IMMUNOPHARMA, INC.
Lyell Immunopharma, Inc. is a United States-based public immunotherapy company founded in 2018. The company has 161 employees and develops cell-based immunotherapies.
Reasons to Buy this Report
- Market Size & Growth Projections : Access precise valuation data for Germany's CAR T-Cell Therapy market with detailed forecasts from 2026-2031, enabling accurate financial planning and investment decisions specific to the German healthcare landscape.
- Competitive Landscape Analysis : Understand Germany's unique competitive dynamics, including local biotech players, international pharmaceutical presence, and market consolidation trends specific to the German CAR T-cell therapy sector.
- Regulatory & Reimbursement Insights : Gain detailed knowledge of Germany's EMA approval pathways, health insurance reimbursement policies, and regulatory requirements that directly impact market entry strategies and commercial viability.
- Clinical Trial & R&D Activity : Identify ongoing clinical trials, research initiatives, and innovation hubs across German institutions, providing intelligence on emerging therapies and partnership opportunities in the German market.
- Strategic Market Entry Planning : Develop targeted go-to-market strategies for Germany with actionable insights on healthcare provider networks, patient demographics, and distribution channels specific to the German healthcare system.
Frequently asked questions
What is the current market size of CAR T-Cell Therapy in Germany?
Germany's CAR T-Cell Therapy market is valued at USD 601.1 million in 2026.
What is the projected market size for CAR T-Cell Therapy in Germany by 2031?
Germany's CAR T-Cell Therapy market is projected to reach USD 1,089.3 million by 2031.
What is the CAGR for Germany's CAR T-Cell Therapy market?
Germany's CAR T-Cell Therapy market is expected to grow at a compound annual growth rate (CAGR) of 12.6% from 2026 to 2031.
What are the primary growth drivers for CAR T-Cell Therapy in Germany?
Key growth drivers in Germany include increasing adoption of personalized cancer therapies, rising prevalence of hematologic malignancies, expanding reimbursement policies, and strong R&D capabilities in the pharmaceutical sector.
Why is Germany a significant market for CAR T-Cell Therapy in Europe?
Germany's advanced healthcare infrastructure, robust regulatory framework, strong pharmaceutical R&D ecosystem, and commitment to precision medicine make it a leading European hub for CAR T-cell innovation and commercialization.
RESEARCH METHODOLOGY
This study involved four major activities in estimating the current size of the CAR T-cell therapy market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), United States Food and Drug Administration (US FDA), American Society of Gene & Cell Therapy (ASGCT), European Medicines Agency (EMA), Industry Association of Synthetic Biology (IASB), International Society for Cell & Gene Therapy (ISCT), National Center for Complementary and Integrative Health (NCCIH), BioPharm International, ScienceDirect, News Articles, Journals, Press Releases, Paid Databases, Expert Interviews, and MarketsandMarkets Analysis, among others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information about major players, global product revenues, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data was collected and analyzed to arrive at the overall size of the global CAR T-cell therapy market, which was validated through primary research.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the CAR T-cell therapy market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
CAR T-Cell Therapy Market Size: Bottom-up Approach and Top-down Approach
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
CAR T-cell therapy is a treatment method wherein a patient’s T-cells (a type of immune system cell) undergo modification in a laboratory to target and attack cancer cells effectively. Initially, T-cells are extracted from the patient’s bloodstream. Then the gene for a special receptor that binds to a specific protein on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is known as a chimeric antigen receptor (CAR). Following this modification process, the CAR T-cells are cultured and multiplied in large quantities. Finally, the amplified CAR T-cells are administered to the patient via infusion. This therapeutic approach is predominantly utilized in the management of specific blood cancers, and ongoing research is exploring its potential applications in treating other forms of cancer. The CAR T-Cell therapy market includes approved and pipeline CAR T-cell products for therapeutic purposes.
Key Stakeholders
- Pharmaceutical Companies
- Biotechnology Companies
- Clinical Research Organizations (CROs)
- Regulatory Authorities
- Healthcare Providers
- Patients and Patient Advocacy Groups
- Investors and Venture Capital Firms
- Research & Development Companies
- Research Laboratories & Academic Institutes.
- Market Research & Consulting Firms
Report Objectives
- To define, describe, and forecast the CAR T-cell therapy market by value for product, target, indication, demographic, end user, and region
- To define, describe, and forecast the CAR T-cell therapy market by volume for the product segment at the global level
- To provide detailed information regarding the major drivers, restraints, opportunities, and challenges, influencing the market growth
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall CAR T-cell therapy market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
- To provide an overview of the market with specialized analysis such as trends/disruptions impacting customers’ business, pricing analysis, value/ supply chain analysis,ecosystem analysis, technology analysis, patent analysis, key conferences & events 2026-2027, regulatory landscape, Porter’s five forces analysis, key stakeholders and buying criteria, and investment and funding scenario
Available customizations:
- With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographic Analysis
- Further breakdown of the Rest of Europe CAR T-cell therapy market, by country
- Further breakdown of the Rest of Asia Pacific CAR T-cell therapy market, by count
Company Information
- Detailed analysis and profiling of additional market players (up to five
Segment Analysis
- Cross-segment analysis
Get the Full CAR T-Cell Therapy Market Report
Full forecast, segment splits, and company analysis for all CAR T-Cell Therapy Market.
- US CAR T-Cell Therapy Market
- Canada CAR T-Cell Therapy Market
- UK CAR T-Cell Therapy Market
- France CAR T-Cell Therapy Market
- Italy CAR T-Cell Therapy Market
- Spain CAR T-Cell Therapy Market
- China CAR T-Cell Therapy Market
- Japan CAR T-Cell Therapy Market
- India CAR T-Cell Therapy Market
- Australia CAR T-Cell Therapy Market
- South Korea CAR T-Cell Therapy Market
- Brazil CAR T-Cell Therapy Market
- UAE CAR T-Cell Therapy Market
- Rest Of Europe CAR T-Cell Therapy Market
- Rest Of Asia Pacific CAR T-Cell Therapy Market
- Rest Of Latin America CAR T-Cell Therapy Market
- GCC Countries CAR T-Cell Therapy Market
- Rest Of Middle East CAR T-Cell Therapy Market
- Kingdom Of Saudi Arabia CAR T-Cell Therapy Market
- Rest Of GCC Countries CAR T-Cell Therapy Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report